Soligenix halts Phase 3 trial of lead drug HyBryte for futility, explores M&A options
Filed April 28, 2026 · Period ending April 28, 2026 · ~1 min read
2 material changes detected in this filing.
Create a free account to read the full summary — it takes 30 seconds.
Partner
Trade SNGX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 2, 2026 10:53 PM